Gamma-aminobutyric acid type A receptor (GABA_A receptor) and other central nervous system ligand-gated ion channels (CNS LGICs) (GABA_A and other LGICs)

Gamma-aminobutyric acid type A (GABA_A) receptors and other central nervous system (CNS) ligand-gated ion channels (LGICs) are a diverse superfamily of transmembrane proteins that mediate rapid chemical signaling between neurons. This broad category encompasses the Cys-loop receptor family—including inhibitory GABA_A and glycine receptors, and excitatory nicotinic acetylcholine receptors—as well as the ionotropic glutamate receptors, such as NMDA, AMPA, and kainate receptors (Source: IUPHAR/BPS Guide to Pharmacology). These channels function by converting the binding of neurotransmitters into electrical signals through the selective movement of ions across the neuronal membrane, which either inhibits or excites the post-synaptic cell. Because they are fundamental to maintaining the balance of neuronal activity, these receptors are implicated in a wide range of neurological and psychiatric disorders, including epilepsy, anxiety, insomnia, and chronic pain (Source: StatPearls, 2023). They serve as primary targets for numerous pharmacological agents, including benzodiazepines, general anesthetics, and anticonvulsants, which modulate channel activity to achieve therapeutic effects. Given their ubiquitous presence and vital role in brain function, they remain among the most significant classes of therapeutic targets in neuropsychopharmacology (Source: Sigel & Steinmann, 2012).

Other names

Ionotropic neurotransmitter receptorsLigand-gated ion channels (LGICs)Cys-loop receptorsIonotropic glutamate receptorsFast-acting neurotransmitter receptors

These receptors act as ligand-activated pores that allow the flow of specific ions (such as chloride, sodium, potassium, or calcium) across the cell membrane, directly altering the neuronal membrane potential. Drugs modulate these channels through various mechanisms: positive allosteric modulation (e.g., benzodiazepines increasing GABA-mediated chloride conductance), negative allosteric modulation, competitive antagonism (e.g., flumazenil), and non-competitive pore blockade (e.g., ketamine blocking the NMDA receptor channel) (Source: IUPHAR/BPS Guide to Pharmacology; StatPearls, 2023).